BCNU (Carmustine) and Gliadel (Carmustine Wafers) - Revision history

Lazy at 08:22, 18 January 2025

2025-01-18T08:22:04Z

← Older revision		Revision as of 01:22, 18 January 2025
Line 129:		Line 129:
	\|notes=While Gliadel wafers alone offer modest improvement, combining them with the standard TMZ protocol seems to significantly improve outcomes.		\|notes=While Gliadel wafers alone offer modest improvement, combining them with the standard TMZ protocol seems to significantly improve outcomes.
	\|treatment_category=Other Chemotherapy and Cancer Drugs		\|treatment_category=Other Chemotherapy and Cancer Drugs
	}}		\|overview=BCNU (Carmustine) and Gliadel (Carmustine Wafers) are FDA-approved treatments for high-grade gliomas, with a median survival of 13.9 months for Gliadel alone and 17 to 20.7 months when combined with Temozolomide (TMZ). While Gliadel wafers provide a localized treatment option that minimizes systemic side effects, they carry significant risks, such as low blood counts and seizures, and are associated with a toxicity level of 4 out of 5.}}

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:33:42Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:33, 12 November 2024
Line 128:		Line 128:

	\|notes=While Gliadel wafers alone offer modest improvement, combining them with the standard TMZ protocol seems to significantly improve outcomes.		\|notes=While Gliadel wafers alone offer modest improvement, combining them with the standard TMZ protocol seems to significantly improve outcomes.
	\|~~category~~=Other Chemotherapy and Cancer Drugs		\|treatment_category=Other Chemotherapy and Cancer Drugs
	}}		}}

Lazy at 20:58, 31 March 2024

2024-03-31T20:58:13Z

← Older revision		Revision as of 13:58, 31 March 2024
Line 77:		Line 77:

	An important variation in the use of BCNU has been the development of polymer wafers		An important variation in the use of BCNU has been the development of polymer wafers
	~~�22~~

	known as gliadel. A number of such wafers are implanted throughout the tumor site at the		known as gliadel. A number of such wafers are implanted throughout the tumor site at the
	time of surgery. BCNU then gradually diffuses from the wafers into the surrounding		time of surgery. BCNU then gradually diffuses from the wafers into the surrounding
Line 124:		Line 122:
	repair of chemotherapy-induced damage, but also causes unacceptable bone marrow		repair of chemotherapy-induced damage, but also causes unacceptable bone marrow
	toxicity when chemotherapy is given systemically. Survival rates at six months, one year		toxicity when chemotherapy is given systemically. Survival rates at six months, one year
	~~�23~~

	and two years were 82%, 47%, and 10%, respectively (59) which seems notably better than		and two years were 82%, 47%, and 10%, respectively (59) which seems notably better than
	the earlier clinical trial with recurrent tumors using gliadel without the 06-BG, in which		the earlier clinical trial with recurrent tumors using gliadel without the 06-BG, in which

Lazy at 18:08, 30 March 2024

2024-03-30T18:08:33Z

← Older revision		Revision as of 11:08, 30 March 2024
Line 8:		Line 8:
	\|usefulness_rating=4		\|usefulness_rating=4
	\|toxicity_level=4		\|toxicity_level=4
			\|toxicity_explanation=The combination of BCNU and Gliadel Wafers in treatment for glioblastoma is assigned a toxicity level of 4, this is relatively high on a scale of 1 to 5. This means that the treatment has serious side effects which may include low blood counts, pulmonary problems, infections, and seizures. Despite these side effects, the improvement in survival rates may make this treatment an important option for many patients. However, managing these side effects could potentially be challenging and may significantly impact the quality of life. It's important to discuss these risks and potential benefits with your healthcare provider.
	\|book_text=The combination of Temodar with BCNU, the traditional chemotherapy for glioblastomas,		\|book_text=The combination of Temodar with BCNU, the traditional chemotherapy for glioblastomas,
	has also been studied, but has been complicated by issues of toxicity and the optimal		has also been studied, but has been complicated by issues of toxicity and the optimal
Line 132:		Line 133:
	\|notes=While Gliadel wafers alone offer modest improvement, combining them with the standard TMZ protocol seems to significantly improve outcomes.		\|notes=While Gliadel wafers alone offer modest improvement, combining them with the standard TMZ protocol seems to significantly improve outcomes.
	\|category=Other Chemotherapy and Cancer Drugs		\|category=Other Chemotherapy and Cancer Drugs
	\|toxicity_explanation=The combination of BCNU and Gliadel Wafers in treatment for glioblastoma is assigned a toxicity level of 4, this is relatively high on a scale of 1 to 5. This means that the treatment has serious side effects which may include low blood counts, pulmonary problems, infections, and seizures. Despite these side effects, the improvement in survival rates may make this treatment an important option for many patients. However, managing these side effects could potentially be challenging and may significantly impact the quality of life. It's important to discuss these risks and potential benefits with your healthcare provider.
	}}		}}

Lazy at 04:18, 28 March 2024

2024-03-28T04:18:54Z

@@ Line 1: / Line 1: @@
 {{TreatmentInfo
-|drug_name=BCNU and Gliadel Wafers
+|drug_name=BCNU (Carmustine) and Gliadel (Carmustine Wafers)
 |FDA_approval=Yes
 |used_for=High-grade gliomas
@@ Line 8: / Line 8: @@
 |usefulness_rating=4
 |toxicity_level=4
-|book_text=BCNU (carmustine) and Gliadel (carmustine wafers)
+|book_text=The combination of Temodar with BCNU, the traditional chemotherapy for glioblastomas,
 The combination of Temodar with BCNU, the traditional chemotherapy for glioblastomas,

Lazy at 16:55, 27 March 2024

2024-03-27T16:55:42Z

← Older revision		Revision as of 09:55, 27 March 2024
Line 7:		Line 7:
	\|OS_with=Gliadel: 13.9 months median survival; Combination with TMZ: Median survival ranges from 17 to 20.7 months		\|OS_with=Gliadel: 13.9 months median survival; Combination with TMZ: Median survival ranges from 17 to 20.7 months
	\|usefulness_rating=4		\|usefulness_rating=4
	\|toxicity_level=3		\|toxicity_level=4
	\|book_text=BCNU (carmustine) and Gliadel (carmustine wafers)		\|book_text=BCNU (carmustine) and Gliadel (carmustine wafers)

Line 74:		Line 74:
	\|notes=While Gliadel wafers alone offer modest improvement, combining them with the standard TMZ protocol seems to significantly improve outcomes.		\|notes=While Gliadel wafers alone offer modest improvement, combining them with the standard TMZ protocol seems to significantly improve outcomes.
	\|category=Other Chemotherapy and Cancer Drugs		\|category=Other Chemotherapy and Cancer Drugs
			\|toxicity_explanation=The combination of BCNU and Gliadel Wafers in treatment for glioblastoma is assigned a toxicity level of 4, this is relatively high on a scale of 1 to 5. This means that the treatment has serious side effects which may include low blood counts, pulmonary problems, infections, and seizures. Despite these side effects, the improvement in survival rates may make this treatment an important option for many patients. However, managing these side effects could potentially be challenging and may significantly impact the quality of life. It's important to discuss these risks and potential benefits with your healthcare provider.
	}}		}}

Lazy at 06:57, 26 March 2024

2024-03-26T06:57:51Z

@@ Line 7: / Line 7: @@
 |OS_with=Gliadel: 13.9 months median survival; Combination with TMZ: Median survival ranges from 17 to 20.7 months
 |usefulness_rating=4
 |notes=While Gliadel wafers alone offer modest improvement, combining them with the standard TMZ protocol seems to significantly improve outcomes.
 |category=Other Chemotherapy and Cancer Drugs
 }}

Lazy: Created page with "{{TreatmentInfo |drug_name=BCNU and Gliadel Wafers |FDA_approval=Yes |used_for=High-grade gliomas |clinical_trial_phase=Phase III (Europe for Gliadel) |common_side_effects=Low blood counts, pulmonary problems, infection, and seizures for Gliadel |OS_with=Gliadel: 13.9 months median survival; Combination with TMZ: Median survival ranges from 17 to 20.7 months |usefulness_rating=4 |notes=While Gliadel wafers alone offer modest improvement, combining them with the standard..."

2024-03-24T13:10:24Z

Created page with "{{TreatmentInfo |drug_name=BCNU and Gliadel Wafers |FDA_approval=Yes |used_for=High-grade gliomas |clinical_trial_phase=Phase III (Europe for Gliadel) |common_side_effects=Low blood counts, pulmonary problems, infection, and seizures for Gliadel |OS_with=Gliadel: 13.9 months median survival; Combination with TMZ: Median survival ranges from 17 to 20.7 months |usefulness_rating=4 |notes=While Gliadel wafers alone offer modest improvement, combining them with the standard..."

New page

{{TreatmentInfo
|drug_name=BCNU and Gliadel Wafers
|FDA_approval=Yes
|used_for=High-grade gliomas
|clinical_trial_phase=Phase III (Europe for Gliadel)
|common_side_effects=Low blood counts, pulmonary problems, infection, and seizures for Gliadel
|OS_with=Gliadel: 13.9 months median survival; Combination with TMZ: Median survival ranges from 17 to 20.7 months
|usefulness_rating=4
|notes=While Gliadel wafers alone offer modest improvement, combining them with the standard TMZ protocol seems to significantly improve outcomes.
|category=Other Chemotherapy and Cancer Drugs
}}